Green stability-indicating RP-HPTLC approach for determining suvorexant in commercial tablet dosage forms

Abstract

A novel sedative/hypnotic drug called suvorexant (SUV) is advised for treating insomnia. From a forensic standpoint, it is important medicine because of its sedative/hypnotic and depressing effects. There are no green “high-performance thin-layer chromatographic (HPTLC)” techniques for measuring SUV in the literature. Therefore, this study aims to develop and validate a reverse-phase HPTLC approach that indicates green stability for SUV measurement in commercially available tablet dosage forms. SUV was detected at 255 nm in wavelength. The suggested SUV analysis approach’s greenness was assessed using the “analytical eco-scale (AES), ChlorTox, and analytical GREEnness (AGREE)” tools. The current SUV analysis method showed linearity in the 10–1200 ng/band range. Furthermore, the SUV analytical method was robust, accurate (% recoveries = 98.18–99.30), sensitive (LOD = 3.32 ng/band and LOQ = 9.98 ng/band), precise (% CV = 0.78–0.94), and environmentally friendly. The “AES, total ChlorTox, and AGREE” scales were derived to be 93, 0.96 g, and 0.88, respectively, using the current SUV analytical method, demonstrating an exceptional greenness profile. SUV was shown to be suitably unstable under oxidative degradation conditions and suitably stable under acid, base, and heat degradation conditions. Furthermore, the SUV analytical method’s stability-indicating component identified SUV in the presence of its breakdown products. It was observed that marketed SUV tablet brands A and B contained, respectively, 98.18 and 101.32% of SUV. The findings of the study indicated that SUV in marketed tablet dosage forms may be monitored on a regular basis with the use of the current green HPTLC methodology.